Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8.

Karanjawala ZE, Illei PB, Ashfaq R, Infante JR, Murphy K, Pandey A, Schulick R, Winter J, Sharma R, Maitra A, Goggins M, Hruban RH.

Am J Surg Pathol. 2008 Feb;32(2):188-96. doi: 10.1097/PAS.0b013e31815701f3.

2.

Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma.

Fukushima N, Koopmann J, Sato N, Prasad N, Carvalho R, Leach SD, Hruban RH, Goggins M.

Mod Pathol. 2005 Jun;18(6):779-87.

3.

Annexin A8 Is a Prognostic Marker and Potential Therapeutic Target for Pancreatic Cancer.

Pimiento JM, Chen DT, Centeno BA, Davis-Yadley AH, Husain K, Fulp WJ, Wang C, Zhang A, Malafa MP.

Pancreas. 2015 Jan;44(1):122-7. doi: 10.1097/MPA.0000000000000218.

4.

NBL1 and anillin (ANLN) genes over-expression in pancreatic carcinoma.

Olakowski M, Tyszkiewicz T, Jarzab M, Król R, Oczko-Wojciechowska M, Kowalska M, Kowal M, Gala GM, Kajor M, Lange D, Chmielik E, Gubala E, Lampe P, Jarzab B.

Folia Histochem Cytobiol. 2009;47(2):249-55. doi: 10.2478/v10042-009-0031-1.

5.

Distinct expression patterns of claudin-1 and claudin-4 in intraductal papillary-mucinous tumors of the pancreas.

Tsukahara M, Nagai H, Kamiakito T, Kawata H, Takayashiki N, Saito K, Tanaka A.

Pathol Int. 2005 Feb;55(2):63-9.

PMID:
15693851
6.

Claudin-18 is an early-stage marker of pancreatic carcinogenesis.

Tanaka M, Shibahara J, Fukushima N, Shinozaki A, Umeda M, Ishikawa S, Kokudo N, Fukayama M.

J Histochem Cytochem. 2011 Oct;59(10):942-52. doi: 10.1369/0022155411420569.

7.

Palladin is overexpressed in the non-neoplastic stroma of infiltrating ductal adenocarcinomas of the pancreas, but is only rarely overexpressed in neoplastic cells.

Salaria SN, Illei P, Sharma R, Walter KM, Klein AP, Eshleman JR, Maitra A, Schulick R, Winter J, Ouellette MM, Goggins M, Hruban R.

Cancer Biol Ther. 2007 Mar;6(3):324-8.

8.

Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas.

Liu H, Shi J, Anandan V, Wang HL, Diehl D, Blansfield J, Gerhard G, Lin F.

Arch Pathol Lab Med. 2012 Jun;136(6):601-9. doi: 10.5858/arpa.2011-0326-OA.

PMID:
22646265
9.

Expression of claudins 7 and 18 in pancreatic ductal adenocarcinoma: association with features of differentiation.

Soini Y, Takasawa A, Eskelinen M, Juvonen P, Kärjä V, Hasegawa T, Murata M, Tanaka S, Kojima T, Sawada N.

J Clin Pathol. 2012 May;65(5):431-6. doi: 10.1136/jclinpath-2011-200400.

PMID:
22396552
10.

Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homolog and heat shock protein 47.

Maitra A, Iacobuzio-Donahue C, Rahman A, Sohn TA, Argani P, Meyer R, Yeo CJ, Cameron JL, Goggins M, Kern SE, Ashfaq R, Hruban RH, Wilentz RE.

Am J Clin Pathol. 2002 Jul;118(1):52-9.

11.

Claudin expression in pancreatic endocrine tumors as compared with ductal adenocarcinomas.

Borka K, Kaliszky P, Szabó E, Lotz G, Kupcsulik P, Schaff Z, Kiss A.

Virchows Arch. 2007 May;450(5):549-57.

PMID:
17429687
12.
13.

Spatiotemporal proteomic analyses during pancreas cancer progression identifies serine/threonine stress kinase 4 (STK4) as a novel candidate biomarker for early stage disease.

Mirus JE, Zhang Y, Hollingsworth MA, Solan JL, Lampe PD, Hingorani SR.

Mol Cell Proteomics. 2014 Dec;13(12):3484-96. doi: 10.1074/mcp.M113.036517.

14.

Identification of novel highly expressed genes in pancreatic ductal adenocarcinomas through a bioinformatics analysis of expressed sequence tags.

Cao D, Hustinx SR, Sui G, Bala P, Sato N, Martin S, Maitra A, Murphy KM, Cameron JL, Yeo CJ, Kern SE, Goggins M, Pandey A, Hruban RH.

Cancer Biol Ther. 2004 Nov;3(11):1081-9; discussion 1090-1.

PMID:
15467436
15.

The developmental transcription factor Gata4 is overexpressed in pancreatic ductal adenocarcinoma.

Karafin MS, Cummings CT, Fu B, Iacobuzio-Donahue CA.

Int J Clin Exp Pathol. 2009 Aug 30;3(1):47-55.

16.

Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.

Shi C, Merchant N, Newsome G, Goldenberg DM, Gold DV.

Arch Pathol Lab Med. 2014 Feb;138(2):220-8. doi: 10.5858/arpa.2013-0056-OA.

17.
18.

Periostin deposition in the stroma of invasive and intraductal neoplasms of the pancreas.

Fukushima N, Kikuchi Y, Nishiyama T, Kudo A, Fukayama M.

Mod Pathol. 2008 Aug;21(8):1044-53. doi: 10.1038/modpathol.2008.77.

19.

ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma.

Grützmann R, Lüttges J, Sipos B, Ammerpohl O, Dobrowolski F, Alldinger I, Kersting S, Ockert D, Koch R, Kalthoff H, Schackert HK, Saeger HD, Klöppel G, Pilarsky C.

Br J Cancer. 2004 Mar 8;90(5):1053-8.

20.

Expression of claudin-4 (CLDN4) mRNA in intraductal papillary mucinous neoplasms of the pancreas.

Tsutsumi K, Sato N, Cui L, Mizumoto K, Sadakari Y, Fujita H, Ohuchida K, Ohtsuka T, Takahata S, Tanaka M.

Mod Pathol. 2011 Apr;24(4):533-41. doi: 10.1038/modpathol.2010.218.

Items per page

Supplemental Content

Support Center